Education
About Us
Working with TipRanks
Follow Us
InnoCan Pharma (INNPF)
OTHER OTC:INNPF
Total Valuation
InnoCan Pharma has a market cap or net worth of $37.48M. The enterprise value is $56.30M.
Market Cap$37.48M
Enterprise Value$56.30M
Share Statistics
InnoCan Pharma has 290,115,500 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding290,115,500
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
InnoCan Pharma’s return on equity (ROE) is -1.15 and return on invested capital (ROIC) is 90.63%.
Return on Equity (ROE)-1.15
Return on Assets (ROA)-0.68
Return on Invested Capital (ROIC)90.63%
Return on Capital Employed (ROCE)0.86
Revenue Per Employee1.24M
Profits Per Employee-427.27K
Employee Count11
Asset Turnover1.97
Inventory Turnover0.96
Valuation Ratios
The current PE Ratio of InnoCan Pharma is -12.78. InnoCan Pharma’s PEG ratio is -0.74.
PE Ratio-12.78
PS Ratio0.00
PB Ratio14.64
Price to Fair Value14.64
Price to FCF-15.21
Price to Operating Cash Flow-15.39
PEG Ratio-0.74
Income Statement
In the last 12 months, InnoCan Pharma had revenue of 13.66M and earned -4.70M in profits. Earnings per share was -0.02.
Revenue13.66M
Gross Profit11.98M
Operating Income3.80M
Pretax Income-4.03M
Net Income-4.70M
EBITDA-3.77M
Earnings Per Share (EPS)-0.02
Cash Flow
In the last 12 months, operating cash flow was -2.39M and capital expenditures -20.00K, giving a free cash flow of -2.41M billion.
Operating Cash Flow-2.39M
Free Cash Flow-2.41M
Free Cash Flow per Share>-0.01
Dividends & Yields
InnoCan Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.16
52-Week Price Change-47.83%
50-Day Moving Average0.13
200-Day Moving Average0.14
Relative Strength Index (RSI)45.68
Average Volume (3m)33.00
Important Dates
InnoCan Pharma upcoming earnings date is Jun 2, 2025, TBA Not Confirmed.
Last Earnings DateMar 31, 2025
Next Earnings DateJun 2, 2025
Ex-Dividend Date―
Financial Position
InnoCan Pharma as a current ratio of 2.68, with Debt / Equity ratio of 0.02%
Current Ratio2.68
Quick Ratio1.99
Debt to Market Cap0.00
Net Debt to EBITDA1.02
Interest Coverage Ratio0.00
Taxes
In the past 12 months, InnoCan Pharma has paid 214.00K in taxes.
Income Tax214.00K
Effective Tax Rate-0.05
Enterprise Valuation
InnoCan Pharma EV to EBITDA ratio is -14.91, with an EV/FCF ratio of -14.23.
EV to Sales4.12
EV to EBITDA-14.91
EV to Free Cash Flow-14.23
EV to Operating Cash Flow-14.40
Balance Sheet
InnoCan Pharma has $5.06M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$5.06M billion.
Cash & Marketable Securities$5.06M
Total Debt$0.00
Net Cash-$5.06M
Net Cash Per Share-$0.02
Tangible Book Value Per Share$0.02
Margins
Gross margin is 90.11%, with operating margin of 27.85%, and net profit margin of -34.41%.
Gross Margin90.11%
Operating Margin27.85%
Pretax Margin-29.54%
Net Profit Margin-34.41%
EBITDA Margin-27.60%
EBIT Margin-27.85%
Analyst Forecast
The average price target for InnoCan Pharma is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―